The ATF4/PSAT1/JNK Signaling Axis Suppresses Ferroptosis to Drive Venetoclax Resistance in AML
{{output}}
Metabolic reprogramming has emerged as a key driver of therapy resistance in acute myeloid leukemia (AML). Here, we identify phosphoserine aminotransferase 1 (PSAT1) as a critical metabolic determinant of venetoclax (VEN) resistance through the suppression of ... ...
